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Abstract
Congenital disorders of glycosylation (CDG) are severe inherited diseases in which aberrant protein glycosylation is a hallmark.
From this genetically and clinically heterogenous group, a significant subgroup due to Golgi homeostasis defects is emerging.
We previously identified TMEM165 as a Golgi protein involved in CDG. Extremely conserved in the eukaryotic reign, the
molecular mechanism by which TMEM165 deficiencies lead to Golgi glycosylation abnormalities is enigmatic. As GDT1 is the
ortholog of TMEM165 in yeast, both gdt1Δ null mutant yeasts and TMEM165 depleted cells were used. We highlighted that the
observed Golgi glycosylation defects due to Gdt1p/TMEM165 deficiency result from Golgi manganese homeostasis defect. We
discovered that in both yeasts and mammalian Gdt1p/TMEM165-deficient cells, Mn2+ supplementation could restore a normal
glycosylation. We also showed that the GPP130 Mn2+ sensitivity was altered in TMEM165 depleted cells. This study not only
provides novel insights into themolecular causes of glycosylation defects observed in TMEM165-deficient cells but also suggest
that TMEM165 is a key determinant for the regulation of Golgi Mn2+ homeostasis.
Introduction
Congenital disorders of glycosylation (CDG) are a rapidly growing
disease family due to genetic defects of protein and lipid glycosy-
lation (1–4). In protein N-glycosylation, two different CDG groups
can be distinguished. In CDG-I, the molecular defects affect the
oligosaccharidic precursor assembly pathway in the endoplas-
mic reticulum, leading to the presence of unoccupied N-glycosy-
lation sites. CDG-II are due to defects in the glycan processing in
the Golgi, giving rise to the presence of abnormal glycan struc-
tures on glycoproteins (5,6). To date, the CDG family comprises
nearly hundred disorders (7). Most are due to defects in the spe-
cific glycosylation machinery, such as SLC35A1 [MIM 605634],
B4GALT1 [MIM 137060] and MGAT2 [MIM 602616]) (8–10). How-
ever, in the CDG-II group, defects have lately been discovered in
proteins that are not only involved in glycosylation but also in
other cellular functions. Among these are CDG caused by altered
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vesicular Golgi trafficking and/or Golgi pH homeostasis marking
a new era in the CDG field (11–16).
In 2012, we reported a novel disorder in this group namely
TMEM165-CDG (17) (OMIM entry #614727). These patients present
a peculiar phenotype includingmajor skeletal dysplasia and hypo-
sialylation and hypogalactosylation of N-glycosylproteins (17,18).
TMEM165 is a transmembrane protein of 324 amino acids belong-
ing to a well conserved but uncharacterized family of membrane
proteins named UPF0016 (Uncharacterized Protein Family 0016;
Pfam PF01169). We demonstrated that TMEM165 is a novel Golgi
protein that can also be found in endocytic pathways (late endo-
somes and lysosomes) (19). We indirectly demonstrated that de-
fects in TMEM165 affect both cytosolic Ca2+ and lysosomal pH
homeostasis (20). Based on these results, we then hypothesized
that TMEM165 could be a Golgi-localized Ca2+/H+ antiporter regu-
lating both Golgi Ca2+ and pH homeostasis (20). Extremely con-
served in the eukaryotic reign, GDT1 is the yeast ortholog of
TMEM165. We showed that the gdt1Δ mutant presents a strong
growth defect phenotype in presence of high concentrations of cal-
cium chloride (500–700 m). In yeast, the Ca2+ Golgi homeostasis
mainly results fromthe activityof Pmr1p, a Golgi P-typeATPase es-
sential to import Ca2+ but also Mn2+ in the Golgi lumen (21–23). Its
activity thenmaintains very lowCa2+andMn2+ concentrations into
the cytosol. Interestingly, it has been shown that Pmr1 inactivation
leads to strong Golgi glycosylation and trafficking defects (24).
The aimof this study is to decipher themolecularmechanism
by which a lack of TMEM165 affects Golgi glycosylation. We used
gdt1nullmutant yeasts and TMEM165 depletedmammalian cells
to unravel this mechanism, and present evidence that in both
yeasts and mammalian cells, the Golgi glycosylation defects
due to a lack of Gdt1p/TMEM165, result fromdefective Golgiman-
ganese homeostasis.
Results
Mn2+ suppresses the Golgi glycosylation defect
of gdt1Δ null mutants cultured in presence of high
Ca2+ concentrations
Wepreviously reported that gdt1Δnullmutants presented a strong
growth defect in the presence of high calcium chloride concentra-
tions such as 700 m (25). To assess whether this growth defi-
ciency was correlated to an abnormal N-linked glycosylation, the
gel mobility of secreted invertase, a protein exclusively N-glycosy-
lated and thus a good reporterofGolgiN-glycosylation efficiency in
vivowas analyzed in the absence and in the presence of increasing
Ca2+ concentrations (Fig. 1A). In yeast, pmr1p is a Golgi Ca2+/Mn2+
P-type ATPase that is involved in maintaining normal Golgi func-
tions, such as glycosylation (21–23). Thus, Pmr1Δ strains, known to
produce and secrete an aberrant form of invertase, lacking high
mannose residues, were taken as positive controls throughout
our experiments (21,23).
While invertase isolated from pmr1Δ strainmigrates on native
gels significantly faster than invertase isolated from a wild-type
strain, no significant differences in the absence of Ca2+ were ob-
served between gdt1Δ and wild-type strains. Strikingly and in the
Figure 1. Mn2+ restores the Golgi glycosylation defect of gdt1Δ null mutants cultured in the presence of high Ca2+ concentrations. (A) High Ca2+ concentrations strongly
affect invertase glycosylation in gdt1Δ strains and partially suppress the glycosylation defect in pmr1Δ strains. N-Glycosylated invertase secreted by wild type, gdt1Δ and
pmr1Δmutantswith orwithout the addition of the indicatedCaCl2 concentrations in themedium. (B)Mn
2+ suppresses the glycosylation defect of the gdt1Δ strains cultured
with 0.5 M CaCl2. N-Glycosylated invertase secreted bywild type, gdt1Δ strains, pmr1Δ and gdt1Δ/pmr1Δ strains with or without the addition of 0.5M CaCl2, with or without
the addition of Mn2+, or with the addition of both 0.5 M CaCl2 and 1 m MnCl2. (C) gdt1p is involved in the suppression of the glycosylation defect in the pmr1Δ strains
cultured in high Ca2+ concentration. N-Glycosylated invertase secreted by wild-type, gdt1Δ strains, pmr1Δ and gdt1Δ/pmr1Δ strains with or without the addition of 0.5 M
CaCl2 or 10 m CaCl2.
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presence of increasing Ca2+ concentrations, invertase secreted
from gdt1Δ strain migrates faster. In wild-type strains, increasing
Ca2+ concentrations had no effects on invertase mobility (data
not shown). As seen in other studies, the increased mobility ob-
served in pmr1pmutant cells cultured in the absence of Ca2+ can
partially be reversed in the presence of Ca2+ (22). These data dem-
onstrate that high environmental Ca2+ concentrations in gdt1Δ
lead to strong N-glycosylation deficiencies while in pmr1Δ, the
observed Golgi N-glycosylation defects are markedly restored
by Ca2+.
In order to understand how high Ca2+ concentrations in gdt1Δ
could lead to glycosylation abnormalities, we hypothesized that
excess of Ca2+ might interfere with glycosylation processes re-
quiring other metal ions including Mn2+ known to be a cofactor
of certain Golgi glycosyltransferases (26). To test this hypothesis,
the invertase mobility was assessed by supplementing the cul-
ture medium with 1 m MnCl2 (Fig. 1B). While this treatment
does not affect the invertase mobility in wild-type strain, Mn2+
treatment completely restores the increased invertase mobility
in gdt1Δ strains cultured in the presence of both Ca2+ and Mn2+.
As previously reported, the Mn2+ supplementation in pmr1Δmu-
tant also greatly improves the invertase mobility (22). This com-
plementation is highly specific for Mn2+ as other tested ions do
not rescue the glycosylation phenotype (Supplementary Mater-
ial, Fig. S1). In order to understand the link between gdt1p and
pmr1p, invertase mobility was analyzed in the gdt1Δ/pmr1Δ dou-
ble knockout. In normal conditions, the invertase mobility is
strongly affected and very similar to the one observed in the
pmr1Δ strains.WhileMn2+ slightly suppressed this Golgi N-glyco-
sylation defect, Ca2+ did not. Very interestingly, this result seems
to show that gdt1p is then crucial for the suppression of the gly-
cosylation defect in the pmr1Δ strains supplemented with Ca2+.
However, since 0.5  CaCl2 already leads to a strong invertase
mobility defect in gdt1Δ strains, a 10 m CaCl2 concentration
was used. In these conditions, no glycosylation defect was ob-
served in gdt1Δ strains, while in pmr1Δ strains 10 m CaCl2 was
sufficient to suppress the glycosylation defect (Fig. 1A and C).
However, this low concentration was not sufficient to rescue
the invertase mobility in the gdt1Δ/pmr1Δ double knock-out,
demonstrating a crucial need for gdt1p in this rescue (Fig. 1C).
These unexpected findings not only demonstrate that the ob-
served Golgi N-glycosylation defect in gdt1Δ strains cultured in
the presence of high Ca2+ concentrations can be suppressed by
the addition of Mn2+ but also that gdt1p is directly involved in the
suppression of the glycosylation defect in the pmr1Δ strains sup-
plemented with Ca2+. Altogether, one can ask the role of gdt1p
in Golgi Mn2+ homeostasis.
Golgi manganese homeostasis is modified in
TMEM165-deficient cell lines
In order to unravel the link between TMEM165, Golgi Mn2+ homeo-
stasis and Golgi glycosylation defects, TMEM165 expression was
depleted using shRNA strategy in HeLa and HEK 293 cells. In
order to avoid the issue of clonal variation, polyclonal populations
of stably expressing cells were generated and used for the study.
ShRNA depletion of TMEM165 in HeLa and HEK 293 cells was
very efficient as 95% of TMEM165 was depleted compared with
control cells (Fig. 2A and C). This decrease was also confirmed by
immunofluorescence staining. As shown in Figure 2B and D,
TMEM165 is absent in TMEM165-depleted cells.
To then assess the Mn2+ Golgi homeostasis in TMEM165-de-
pleted cells, we took advantage of the Golgi protein GPP130 that
is known to be a specific Golgi Mn2+ sensor (27,28). In mammalian
cell lines, it has been shown by several authors that the stability of
GPP130was strictly dependent onGolgiMn2+ concentration. In the
presence of 500 µ MnCl2, GPP130 was shown to be targeted to
lysosomal degradation via a Rab7-dependent mechanism (28).
The stability of GPP130 was studiedwith andwithout MnCl2 treat-
ment by western blot and immunofluorescence in shTMEM165
HeLa andHEK293 cells (Figs 3 and 4). In accordancewith the litera-
ture, we showed that the level of GPP130was significantly reduced
when control cells were cultured with Mn2+ (Figs 3A and 4A and
quantification in Figs 3B and 4B). Interestingly, this Mn2+-induced
degradation is strongly delayed in TMEM165-depleted cells. Quan-
tification indicated that GPP130 loss exceeded 60% in control HeLa
cells after 4 hMn2+ treatment while only a 20% decrease is seen in
shTMEM165 HeLa cells. We can notice that in HEK293 cells, the
effects of Mn2+ on GPP130 stability are less pronounced as
GPP130 loss exceeded only 40% in control HEK293 cells after 16 h
of Mn2+ treatment. Similarly to shTMEM165 HeLa cells, the Mn2+
treatment had no effects on GPP130 stability in shTMEM165
HEK293 cells. Immunofluorescence staining followed by confocal
microscopy confirmed the western blot results for both HeLa and
HEK293 cells (Figs 3C and 4C and quantification in Figs 3D and 4D).
Altogether, these data highly suggest that the Golgi Mn2+ homeo-
stasis is impaired in TMEM165-depleted cells.
As shown by Mukhopadhyay and collaborators, high concen-
trations of extracellular Mn2+ induces rapid redistribution of
GPP130 in vesicles before their lysosomal degradation. As HeLa
cells were shown to be more sensitive to Mn2+ treatment, we
decided to investigate thedifferential impact ofMn2+ on thevesicu-
lar redistribution of GPP130 in shTMEM165 HeLa cells compared
with control cells. The redistributionof GPP130was followedby im-
munofluorescence in response to different times ofMn2+ exposure
(Fig. 5). In the absence of Mn2+, GPP130 is Golgi localized in both
control and shTMEM165 HeLa cells (Fig. 5A and C). After 1 and
2 h of Mn2+ treatment in control cells, GPP130 is delocalized in
punctate structures (∼20 GPP130 positive structures per cell have
been quantified) decreasing to <10 positive structures per cell
after 4 h of Mn2+ treatment. Remarkably and after Mn2+ exposure,
thenumberof positiveGPP130punctuatestructures in shTMEM165
cells is extremely low (∼5 per cell). This confirms the western blot
result and demonstrates the insensitivity of GPP130 to Mn2+ treat-
ment in shTMEM165 HeLa cells. As the GPP130 luminal stem do-
main has been demonstrated to confer this Mn2+ sensitivity, our
results highly suggest that TMEM165 is required to regulate Golgi
Mn2+ homeostasis.
TMEM165 knockdown provokes a glycosylation defect
that can be suppressed by manganese supplementation
As we previously showed that Golgi glycosylation deficiency in
gdt1Δ strains can be suppressedby the additionofMnCl2 in theme-
dium, we wanted to investigate in TMEM165-depleted cells (i) the
glycosylation defect and (ii) the impact of Mn2+ supplementation
on the suppression of the glycosylation defect. To evaluate these
twoaspects,wefirst determined the steady-state glycosylation sta-
tus of LAMP2, an extensively N-glycosylated lysosomal resident
protein and TGN46, a glycoprotein known to be N- and O-glycosy-
lated. For this, control and shTMEM165HeLaandHEK293 cellswere
treated or not with MnCl2 (Fig. 6). While a subtle change in the
LAMP2 mobility arguing for slight heterogeneity in glycosylation
could be observed between control and shTMEM165 HeLa cells
(Fig. 6A), a more pronounced decrease in TGN46 molecular weight
was observed compared with control cells (Fig. 6A). Remarkably,
when Mn2+ was added to the cell culture, the altered gel mobility
of LAMP2 and TGN46 was completely suppressed in shTMEM165
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HeLa cells. Comparablewith the shTMEM165 HeLa results, a stron-
ger increase in both LAMP2 and TGN46 gel mobility was observed
in shTMEM165 HEK293 cells (Fig. 6B). Very interestingly, the ob-
served increased gel mobility was also suppressed for these two
glycoproteins after Mn2+ treatment. To appreciate the specific
effect of the Mn2+, shTMEM165 HEK293 cells were treated with
MnSO4. Similarly to MnCl2, MnSO4 completely suppresses the ob-
served heterogeneity in gel mobility (Supplementary Material,
Fig. S2). To confirm that Mn2+ rescues the glycosylation process,
shTMEM165 HEK293 cells treated or not with Mn2+, were subjected
to PNGase F treatment (SupplementaryMaterial, Fig. S3).We found
that deglycosylation of LAMP2 produced a 40 kDa polypeptide for
both (Supplementary Material, Fig. S3A). For TGN46 and in the ab-
senceofMn2+, PNGase F treatment leads only toa slight increase in
gelmobilityarguing that among the potentialN-glycosylation sites
of TGN46, only few of them are N-glycosylated (Supplementary
Material, Fig. S3B). We interestingly found that deglycosylation of
TGN46 from shTMEM165 HEK293 cells treated withMn2+ produces
a band with a higher molecular weight than the one obtained in
untreated shTMEM165 cells. Altogether, these results suggest
that Mn2+ rescues the N-glycosylation for LAMP2 and likely the
O-glycosylation for TGN46. It is important to note that the glycosy-
lation defect observed for both LAMP2 and TGN46 in shTMEM165
HEK293 cells does not lead to an aberrant subcellular localization
for these two proteins (Supplementary Material, Fig. S4).
To confirm the Mn2+ effects, mass spectrometry analysis of
N-glycans was performed in control and shTMEM165 HEK293
cells treated or not with Mn2+ (Fig. 7). The structures detected
at mass-per-charge (m/z) ratios >2966 were found absent in
shTMEM165 HEK293 cells compared with control cells then dem-
onstrating a severe Golgi processing defect. Remarkably, the struc-
tures detected at mass-per-charge (m/z) ratios 1345, 1416, 1591,
1836, 1907, 2040, 2081, 2285, 2326, 2850 and 2891 were found in in-
creased abundance in shTMEM165 cells in comparison with those
Figure 2. Generation and characterization of shTMEM165 HeLa and HEK293 cells. (A) Steady-state cellular level of TMEM165. HeLa cells weremock (control) or depleted in
TMEM165 (shTMEM165). Total cell lysates were prepared, subjected to SDS–PAGE and western blot with the indicated antibodies. Right panel represents quantification of
TMEM165. (B) Control and shTMEM165 HeLa cells were fixed and labeled with antibodies against TMEM165 and GM130 before confocal microscopy visualization. (C)
Steady-state cellular level of TMEM165. HEK293 cells were mock (control) or depleted in TMEM165 (shTMEM165). Total cell lysates were prepared, subjected to SDS–
PAGE and western blot with the indicated antibodies. Lower panel represents quantification of TMEM165. (D) Control and shTMEM165 HEK293 cells were fixed and
labeled with antibodies against TMEM165 before confocal microscopy visualization. Lower panel shows the GFP, coded by the pGIPZ Lentiviral shRNA plasmid
(Thermo Scientific) used for the generation of our cell lines.
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observed in control cells. These results highlight a strong galacto-
sylation, amoderateGlcNAcylation defect and a very slight sialyla-
tion defect in shTMEM165 HEK293 cells. While Mn2+ treatment
have no obvious effects on control HEK293 cells, such treatment
largely suppresses the observed glycosylation defects, mainly the
galactosylation defect, as observed by the decreased abundance
of the structures (m/z) 1836 and 2081. This demonstrates that a
defect in TMEM165 impairs the function of Golgi Mn2+-dependent
enzymes,mainly the β-1,4-galactosyltransferase I. AsMn2+ supple-
mentation could be considered as a treatment option, different
Mn2+ concentrations (1–50 µM) have been tested. Interestingly,
we observe that only 1 µ was sufficient to completely suppress
the glycosylation defect observed in shTMEM165 HEK293 cells for
both TGN46 and LAMP2 (Fig. 8). Altogether and in agreement
with the yeast results, we demonstrated that (i) the underlying
pathomechanism of TMEM165 deficiency is linked to Golgi Mn2+
homeostasis defect and (ii) the impaired Golgi glycosylation
could totally be rescued by the addition of Mn2+.
Discussion
TMEM165 deficiency was recently found to lead to a type-II CDG
associated with defective Golgi N-glycosylation. TMEM165/Gdt1p
is extremely conserved during evolution, and has no known direct
molecular function. TMEM165/Gdt1p is not directly involved in the
Golgi glycosylation process, as it is neither a sugar transporter nor
Figure 3.Mn2+ does not alter the stability of GPP130 in TMEM165-deficient HeLa cell lines (A) Steady-state cellular level of GPP130. Control and shTMEM165HeLa cells were
treated or not with MnCl2 500 µM during 4 h. Total cell lysates were prepared, subjected to SDS–PAGE and western blot with the indicated antibodies. (B) Quantification of
GPP130 protein after normalization with actin (N = 3; ***P-value <0,001). (C) Control and shTMEM165 HeLa cells were incubated with MnCl2 500 µM during 4 h or 100 µM
during 16 h, fixed and labeled with antibodies against GPP130 (upper panels) and GM130 (lower panels) before confocal microscopy visualization. (D) Quantification of
the associated GPP130 fluorescence intensity (number of experiments (N) = 3; number of cells (n) = 50; ***P-value <0.001).
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aGolgi glycosyltransferase. Previousworkhas shown that a lackof
Gdt1p leads to a sensitivity to high Ca2+ concentrations and we
have demonstrated that TMEM165 is involved in pH homeostasis
(20). These results led us to hypothesize that Gdt1p/TMEM165
could be a Ca+/H+ antiporter involved in the Golgi Ca2+ entrance
and exit of H+. In this study, we showed that high environmental
Figure 4.Mn2+ does not alter the stability of GPP130 in TMEM165-deficient HEK293 cell lines. (A) Steady-state cellular level of GPP130. Control and shTMEM165HEK293 cells
were treated or not with MnCl2 100 µ during 16 h. Total cell lysates were prepared, subjected to SDS–PAGE and western blot with the indicated antibodies.
(B) Quantification of GPP130 protein after normalization with actin (N = 2; ***P-value <0.001). (C) Control and shTMEM165 HEK293 cells were incubated with MnCl2
100 µM during 16 h, fixed and labeled with antibodies against GPP130 (upper panels) and GM130 (lower panels) before confocal microscopy visualization. DAPI
staining was performed and shows the nucleus. (D) Quantification of the associated GPP130 fluorescence intensity (number of experiments (N) = 2; number of cells
(n) = 50; ***P-value <0.001).
1494 | Human Molecular Genetics, 2016, Vol. 25, No. 8
 at K
U
 Leuven U
niversity Library on M
arch 30, 2016
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
Ca2+ concentrations in gdt1Δ led to strong N-glycosylation defi-
ciencies while in pmr1Δ, the observed Golgi N-glycosylation
defects were markedly suppressed in the presence of Ca2+. This
antagonistic effect then implied different functions for these two
proteins. Interestingly, previous work has also shown that the ob-
served Golgi glycosylation defects in pmr1Δ were not due to the
lack of Ca2+ uptake but mainly to a lack of Mn2+ uptake. Moreover,
addingMn2+ to the culturemediumcan rescue theN-glycosylation
defect of the pmr1Δ strains (22). We therefore hypothesized that
the observed glycosylation defect in gdt1Δ could also be linked to
a decrease in Mn2+ Golgi homeostasis. In that case, the addition
of Mn2+ to the culture medium could be sufficient to complement
the glycosylation deficiency observed in the presence of high Ca2+
concentrations. In order to explore this hypothesis, Mn2+ and
other cations were tested in gdt1Δ yeasts. Interestingly, 1 m
MnCl2 was sufficient to completely suppress the glycosylation de-
ficiency seen in the presence of high calcium concentration.
Why is the glycosylation deficiency only seen in the presence
of high calcium concentration in gdt1Δ yeasts? One part of the an-
swer certainly resides in the fact that Pmr1p is a Ca2+/Mn2+ trans-
porter. It is then tempting to hypothesize that a high Ca2+
concentration could prevent the import of Mn2+ via Pmr1p into
the Golgi via a dilution phenomenon. In the absence of Gdt1p,
the import of Mn2+ into the Golgi compartment would not be suf-
ficient to generate theMn2+ homeostasis required for Golgi glyco-
syltransferases activities. The Mn2+-dependent catalytic activity
is indeed a characteristic of many Golgi glycosyltransferases in
yeasts such as MNN1, MNN2 and MNN5 (29,30). Therefore and
in the presence of high Ca2+ concentration, their activities
would be likely altered in the absence of Gdt1p.
Theotherpossibility thatwecannotcompletelyexclude isadir-
ect competition between Ca2+ and Mn2+ inside the Golgi lumen. In
that case, Gdt1p would function as an extruder of Ca2+ from the
Golgi lumen to lower the competition between Ca2+ and Mn2+.
The Mn2+ import into the Golgi could also be indirect. Two Mn2+
transporters exist in the yeast secretory pathway, Smf1p and
Smf2p that allows theMn2+ import in the ER and TGN/endosomes,
respectively. One can then imagine that the lack of Gdt1p disturbs
the functions and/or localization of these transporters in the pres-
ence of high Ca2+ concentration then causing indirectly a defi-
ciency of Golgi Mn2+ import (31). Interestingly, we also showed
that gdt1p is directly involved in the suppression of the glycosyla-
tion defect in the pmr1Δ strains supplementedwith Ca2+. This sug-
gests that thepresenceof Ca2+ increases theGolgiMn2+uptake, and
that thismolecular process ismediated by gdt1p. From these yeast
data, we could propose amodel where Gdt1pwould act as an anti-
porter or cotransporter ofMn2+/Ca2+. As anabnormal lysosomalpH
hasbeenhighlighted inTMEM165-deficientCDGpatients,we could
imagine that the used counterion for Mn2+ entry would be differ-
ent, H+ for mammalian cells and Ca2+ for yeasts.
As the regulation ofMn2+ homeostasis is highly conserved be-
tween yeasts and higher eukaryotes, we assessed the impact of
Mn2+ on Golgi glycosylation in TMEM165-depleted cells (HeLa
and HEK293). We first wanted to highlight that the Golgi Mn2+
homeostasis was impaired in TMEM165-depleted cells by using
GPP130 as an intra-Golgi Mn2+ sensor. We clearly showed that
in TMEM165-depleted cells, compared with control cells, the
GPP130Mn2+ sensitivitywas altered. As the luminal stemdomain
was sufficient to confer Mn2+ sensitivity to the protein, our re-
sults support a model where the Golgi Mn2+ homeostasis would
be disrupted in TMEM165-depleted cells. Interestingly, we ob-
served that the effect of shTMEM165 on GPP130 degradation
was stronger in HeLa when compared with HEK293 cells. The
Mn2+ concentration inside the Golgi is mainly depending of two
Figure 5. Alteration of the Mn2+ associated GPP130 vesicularization in shTMEM165 cells. (A) Control and shTMEM165 HeLa cells were incubated withMnCl2 500 µ during
the indicated times, fixed and labeledwith antibodies against GPP130 (upper panels) andGM130 (lower panels) before confocalmicroscopy visualization. (B) Magnification
of the 1 h panel presented in A. Cells were immunostained with anti-GPP130 (left panels) and anti-GM130 antibodies (right panels). (C) Quantification of the average
number of GPP130 positive vesicles per cell in control and shTMEM165 HeLa cells (N = 2; n = 50; ***P-value <0.001).
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factors (i) the uptake of Mn2+ from the cytosol into the Golgi
(mainly depending of the Ca2+/Mn2+-ATPase and certainly other
transporters) and (ii) the intake of Mn2+ from the extracellular
medium into the cytosol (depending of the plasma membrane
expression of Mn2+ transporters). As increased Mn2+ concentra-
tion in the culture medium has a stronger effect on GPP130 deg-
radation in HeLa cells as compared to HEK293 cells, one can
suppose that the Mn2+ intake is very efficient in HeLa compared
to HEK293 cells. This could also explain why the glycosylation
defect is very subtle in HeLa cells compared with HEK293 cells.
The impact of Mn2+ on Golgi glycosylation was assessed by
mass spectrometry and by following the migration profile of two
highly glycosylated proteins. While the migration was shown to
be altered for both LAMP2 and TGN46 in both shTMEM165 HeLa
andHEK293 cells, theMn2+ treatment did completely restore a pro-
tein mobility comparable with that observed in control cells Ana-
lysis of N-linked glycans from glycoproteins using MALDI-TOF
mainly showed the accumulation of agalactosylated glycan struc-
tures in TMEM165-depleted HEK293 cells arguing for a severe ga-
lactosylation defect. In line with the western blot results, Mn2+
treatment almost totally suppressed the observed glycosylation
defect. This galactosylation defect is very interesting and seems
to be a general characteristic of the cellular Mn2+ impairment.
The recent discovery of CDG patients presenting strong galactosy-
lation defects on serotransferrin and carrying SLC39A8mutations,
a Zn2+/Mn2+ transporter, emphasizes the link between Golgi Mn2+
homeostasis andGolgi galactosylation efficiency process (32). Two
Golgi galactosyltransferases are known to transfer Gal residues
fromUDP-Gal to terminalN-acetylglucosamine (GlcNAc) residues,
the UDP-Gal:N-acetylglucosamine β-1,4-galactosyltransferase I
(B4GALT1; EC 2.4.1.22) that synthesizes N-acetyl lactosamine
structuresonglycoproteins and theUDP-Gal:N-acetylglucosamine
β-1,4-galactosyltransferase II (B4GALT2; EC 2.4.1.22) that both act
on glycoproteins and glycolipids. From a general point of view,
these enzymes as well as the Golgi glycosyltransferases using
UDP-sugars as a donor substrate, absolutely require Mn2+ for
their activities. This could also explainwhy theGlcNAcylationpro-
cess is also impaired in TMEM165-depleted HEK293 cells.
Altogether, these experiments confirmed that in both yeasts
and mammalian cells, the glycosylation abnormalities due to
Gdt1p/TMEM165 defects are rescued by the addition of Mn2+.
In conclusion, we demonstrated that the observed Golgi gly-
cosylation deficiencies in Gdt1p/TMEM165-deficient cells result
from a defective Golgi Mn2+ homeostasis. This study provides
Figure 6.Mn2+ suppresses the observed LAMP2 and TGN46 altered gel mobility in TMEM165-depleted cells. (A) Steady-state cellular level and gel mobility of LAMP2 and
TGN46 in control and shTMEM165 HeLa cells. (B) Steady-state cellular level and gel mobility of LAMP2 and TGN46 in control and shTMEM165 HEK293 cells. Control and
shTMEM165 cells were cultured in the absence or presence of MnCl2 (100 µM) during 18 h, cell lysates were prepared, subjected to SDS–PAGE and western blot with the
indicated antibodies.
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Figure 7.Mn2+ suppresses the observed galactosylation defect in TMEM165 depleted cells. (A) MALDI-TOF-MS spectra of the permethylated N-glycans from control HEK293
cells. (B) MALDI-TOF-MS spectra of the permethylated N-glycans from control HEK293 cells treated with Mn2+ 100 µM for 36 h. (C) MALDI-TOF-MS spectra of the
permethylated N-glycans from shTMEM165 HEK293 cells. (D) MALDI-TOF-MS spectra of the permethylated N-glycans from shTMEM165 HEK293 cells treated with Mn2+
100 µM for 36 h. The proposed glycan structures are in accordance with the Golgi biosynthetic pathway. The symbols representing sugar residues are as follows: closed
square, N-acetylglucosamine; open circle, mannose; closed circle, galactose; open diamond, sialic acid; and closed triangle, fucose. Linkages between sugar residues have
been removed for simplicity.
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novel insights into the mechanism of the galactosylation defect
observed in TMEM165-deficient cells. These findings also support
the potential use of therapeutic trials of Mn2+ in TMEM165-
deficient patients.
Material and Methods
Yeast strains and media
Yeast strains originating from BY4741 background used for the
experiments are listed
Wild type: Mata his3Δ1 leu2Δ0 ura3Δ0
pmr1Δ: Mata his3Δ1 leu2Δ0 ura3Δ0 pmr1Δ::KanMX4
gdt1Δ: Mata his3Δ1 leu2Δ0 ura3Δ0 gdt1Δ::KanMX4
gdt1Δ /pmr1Δ: Mata his3Δ1 leu2Δ0 ura3Δ0 gdt1Δ::KanMX4
pmr1Δ::KanMX4
Yeasts were cultured at 30°C. Cultures in liquid media are done
under a light shaking. Rich media, named YEP media, contains
yeast extract (10 g L−1, Difco), Bacto-peptone (20 g L−1, Difco). YPD
media is a YEP media supplemented with 2% -glucose (Sigma-
Aldrich). YPR is YEP supplementedwith 2% raffinose (Euromedex).
Selection antibiotics were added at 100 µg mL−1 for nourseothri-
cine and 200 µgmL−1 for G418.
Invertase glycosylation analysis
Before any analysis, a preculture in YPDmedia is done and a vol-
ume equivalent to 15 OD600nm units is centrifugated for 3 min at
3500 rpm. The supernatant is discarded and the pellet is resus-
pended in YPR media to induce invertase expression. Calcium,
manganese and other ions were added at this step at the indi-
cated concentration. After a 20 h culture in YPR, yeasts were cen-
trifugated for 5 min at 3500 rpm. Supernatant was discarded and
the pellet was kept frozen at −20°C. Invertase glycosylation ana-
lysis was performed as described by Ballou et al. (33).
Antibodies and other reagents
Anti-TMEM165 and anti-β actin antibodies were from Sigma-
Aldrich (St Louis, MO, USA). Anti-GM130 antibody was from BD
Biosciences (Franklin lakes, NJ, USA). Anti-GPP130 antibody was
purchased from Covance (Princeton, NJ, USA). Goat anti-rabbit or
goat anti-mouse immunoglobulins HRP conjugated were pur-
chased fromDako (Glostrup, Denmark). Polyclonal goat anti-rabbit
or goat anti-mouse conjugated with Alexa Fluor was purchased
from Thermo Fisher Scientific (Waltham, MA, USA). PNGase F
was from Roche Diagnostics (GmbH, Penzberg, Germany). Other
chemicals were from Sigma-Aldrich unless otherwise specified.
Cell culture and transfections
All cell lines weremaintained in Dulbecco’smodified Eagle’sme-
dium supplemented with 10% fetal bovine serum (FBS; Lonza,
Basel, Switzerland), at 37°C in humidity-saturated 5% CO2 atmos-
phere.We generated polyclonal HeLa andHEK293 stable cell lines
knockdown for TMEM165 by the shRNA technique. Cells were
transfected with the pGIPZ Lentiviral shRNA plasmid (Thermo
Fisher Scientific) containing either shRNA sequences targeting
TMEM165 mRNA or no sequences. The selection was done with
puromycine. Thus, we generated two polyclonal cell lines,
named control cell line and shTMEM165 for the cell line depleted
in TMEM165. For manganese treatment, MnCl2 was added for the
times and concentrations described in each figures.
Immunofluorescence staining
Cells were seeded on coverslips for 12–24 h, washed once in Dul-
becco’s phosphate-buffered saline (DPBS, Lonza) and fixed either
with 4% paraformaldehyde (PAF) in phosphate-buffered saline
(PBS), pH 7.3, for 30 min at room temperature or with ice-cold
methanol for 10 min at room temperature. Coverslips were then
washed three times with PBS. Only if the fixation had been done
with PAF, cells were permeabilized with 0.5% Triton X-100 in PBS
for 15 min then washed three times with PBS. Coverslips were
Figure 8.Onemicromolar ofMnCl2 is sufficient to suppress the glycosylation defect observed in shTMEM165HEK293 cells for both TGN46 and LAMP2. Steady-state cellular
level and gel mobility of LAMP2 and TGN46 in control and shTMEM165 HEK293 cells. Cells were cultured in the absence or presence of MnCl2 during 36 h, cell lysates were
prepared, subjected to SDS–PAGE and western blot with the indicated antibodies.
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then put in saturation for 1 h in blocking buffer [0.2% gelatin, 2%
bovin serum albumin (BSA), 2% FBS (Lonza) in PBS], followed by
the incubation for 1 h with primary antibody diluted at 1:100 in
blocking buffer. After washing with PBS, cells were incubated
for 1 h with Alexa 488-, Alexa 568- or Alexa 700-conjugated sec-
ondary antibody (Life Technologies) diluted at 1:600 in blocking
buffer. After three washing with PBS, coverslips were mounted
on glass slides with Mowiol. Fluorescence was detected through
an inverted Leica TCS-SP5 confocal microscope. Acquisitions
were done using the LAS AF LITE software 2.6.3 (Leica Microsys-
tem, Wetzlar, Germany).
Image analyses
Immunofluorescence images were analyzed using TisGolgi, an
homemade imageJ (35) (http://imagej.nih.gov/ij, 3 February 2016,
date last accessed) plugin developed by TISBio and available
upon request. Basically, the program automatically detects and
discriminates Golgi and vesicles, based on morphological para-
meters such as size and sphericity. Then, the program calculates
for each image the number of detected objects, their size and
mean fluorescence intensity.
PNGase F deglycosylation assay
Fifty micrograms of cell lysate are vacuum dried with Speed-
Vac™. Samples are then dissolved in 200 µl ammonium bicar-
bonate 50 m buffer. Five microliters of a solution containing
10% SDS and 10% β-mercaptoethanol in ammonium bicarbonate
50 m are added to the samples. Heat for 10 min at 100°C. Cool
down the samples at room temperature and add 175 µl of ammo-
nium bicarbonate 50 m buffer. Add 25 µl of a solution contain-
ing 10% NP-40 in ammonium bicarbonate 50 m. To perform the
deglycosylation treatment, add 1,5 PNGase F unit to each sample
and put the samples at 37°C overnight. Samples are then vaccum
dried with SpeedVac™ and then dissolved in NuPAGE LDS sam-
ple buffer (Invitrogen) pH 8.4 supplemented with 4% β-mercap-
toethanol (Fluka).
Western blotting
Cells were scraped in DPBS and then centrifuged at 4500 rpm for
3 min. Supernatant was discarded and cells were then resus-
pended in RIPA buffer [Tris–HCl 50 m, pH 7.9, NaCl 120 m,
NP40 0.5%, EDTA 1 m, Na3VO4 1 m, NaF 5 m] supplemented
with a protease cocktail inhibitor (Roche Diagnostics, Penzberg,
Germany). Cell lysis was done by passing the cells several times
through a syringe with a 26G needle. Cells were centrifuged for
30 min at 20 000 × g. The supernatant containing protein was es-
timatedwith themicro BCA ProteinAssayKit (Thermo Scientific).
Twenty micrograms of total protein lysate were put in NuPAGE
LDS sample buffer (Invitrogen), pH 8.4, supplemented with 4%
β-mercaptoethanol (Fluka). Samples were heated 10 min at 95°C
and then separated on 4–12% Bis–Tris gels (Invitrogen) and trans-
ferred to nitrocellulose membrane Hybond ECL (GE Healthcare,
Little Chalfont, UK). The membrane was blocked in blocking buf-
fer (5% milk powder in TBS-T [1× TBS with 0.05% Tween 20]) for
1 h at room temperature, then incubated overnight with the pri-
mary antibodies in blocking buffer, and washed three times for
5 min in TBS-T. The membranes were then incubated with the
peroxidase-conjugated secondary goat anti-rabbit or goat anti-
mouse antibodies (Dako; used at a dilution of 1:10 000) in blocking
buffer for 1 h at room temperature and later washed three times
for 5 min in TBS-T. Signal was detected with chemiluminescence
reagent (ECL 2 Western Blotting Susbtrate, Thermo Scientific) on
imaging film (GE Healthcare, Little Chalfont, UK).
Glycan analysis by mass spectrometry
Cells were sonicated in extraction buffer (25 m Tris, 150 m
NaCl, 5 m EDTA and 1% CHAPS, pH 7.4) and then dialyzed in
6–8 kDa cut-off dialysis tubing in an ammonium bicarbonate so-
lution (50 m, pH 8.3) for 48 h at 4°C and lyophilized. The pro-
teins/glycoproteins were reduced and carboxyamidomethylated
followed by sequential tryptic and peptideN-glycosidase F diges-
tion and Sep-Pak purification. Permethylation of the freeze-dried
glycans and MALDI-TOF-MS of permethylated glycans were per-
formed as described elsewhere (34).
Statistical analysis
Comparisons between groups were performed using Student’s
t-test for two variables with equal or different variances, depend-
ing on the result of the F-test.
Supplementary Material
Supplementary Material is available at HMG online.
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